医疗和牙科

Stratasysand CollPlant joint development addresses $2.6B bioprinting market opportunity

Stratasysand胶结植物have announced plans to “transform healthcare with industrial scale bioprinting of tissues and organs.” To establish a method for bio-fabricating human tissues and organs utilizing CollPlant Biotechnologies’ rh-Collagen-based bioinks and Stratasys Ltd’s P3 technology-based bioprinter, the two companies have signed a cooperative development and commercialization agreement. The first project focuses on making a solution for CollPlant’s program for regenerative breast implants that can be used on an industrial scale.

正在开发基于套管基于植物的胶原蛋白的创新技术和解决方案正在开发用于组织再生和器官生产。Collplant是一家开创性的再生和审美医学公司。

The new bioprinter will make it possible to make CollPlant’s cutting-edge breast implants. These implants are being made so that a person’s natural breast tissue can grow back without triggering an immune response. This could be a game-changing option for both cosmetic and reconstructive surgery. The bioprinter is based on Stratasys’ precise P3 3D printing technology in combination with CollPlant’s flagship bioinks.

Stratasys的P3自动生产单元格。照片由Mael Duportal。
Stratasys在FormNext的P3自动生产单元。照片由Mael Duportal。

26亿美元的市场机会

胶结植物is working on cutting-edge breast implants that will help a person’s natural breast tissue grow back without triggering an immune response. Based on Stratasys’ precise P3 3D printing technology and CollPlant’s flagship bioinks, the new bioprinter will be used to make these implants. This could represent a ground-breaking alternative for both aesthetic and reconstructive procedures.

隆胸和重建治疗现在在全球范围内执行的所有整容手术程序中排名第二,市场价值为26亿美元。大多数隆胸和重建手术是通过合成有机硅乳房植入物进行的,这是一种自然再生组织的人造替代品,可能引起问题。

根据该协议,这两家企业都将互相交叉彼此的生物打印商品。客户可以和Collplant的生物互联一起购买Stratasys的生物生产商,反之亦然,可用于Colleplant的客户和业务合作伙伴。

客户可以和Colleplant的生物互联一起购买Stratasys的生物生产商;同样,Stratasys的Bioprointer将提供给Colleplant的客户和业务合作伙伴。

Bottles of CollPlant rhCollagen bioink. Image via CollPlant
Bottles of CollPlant rhCollagen bioink. Image via CollPlant

According to Stratasys CEO Dr. Yoav Zeif, “through this partnership with CollPlant, we have an important opportunity to transform healthcare with bioprinting in order to improve the lives of patients undergoing breast augmentation or reconstruction procedures.” The production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerization technology are particularly well suited for bioprinting applications, and this agreement is in line with the company’s strategy to deliver complete solutions for high-growth industry applications with its ecosystem of partners. “We believe that partnering with CollPlant will enable us to accelerate the industrialization of bioprinting for regenerative medicine, and we look forward to collaborating towards the successful commercialization of CollPlant’s novel regenerative breast implants and beyond,” added Zeif.

Stratasys公司是一个加法制造的领导者,一个雷电竞充值nd Yehiel Tal, CEO of CollPlant, is excited to work with them on this project that will change the game. “P3 technology allows printing with high resolution and process control, and we believe that the combined, pioneering technologies of both companies will streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants and other potential tissues and organs. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer,” said the CollPlant CEO.

CollPlant宣布2023年1月,往下cessfully completed large-animal research for its 3D bioprinted regenerative breast implants. After three months, the preclinical investigation showed increasing phases of tissue regeneration, as evidenced by the development of connective tissue and neovascular networks within the implants, all without any adverse effects being observed. Based on these promising findings, CollPlant intends to launch large-animal follow-up research in the second half of 2023, employing implants of commercial size to aid in upcoming human investigations and product commercialization.

What does the3D打印的未来hold?

Whatengineering challengesneed to be tackled in the additive manufacturing sector?

要了解最新的3D印刷新闻,请不要忘记订阅3D打印行业通讯或跟随我们Twitter, or like our page onFacebook

当您在这里时,为什么不订阅我们YouTubechannel? Featuring discussion, debriefs, video shorts, and webinar replays. Are you looking for a job in the additive manufacturing industry? Visit3D打印作业for a selection of roles in the industry.

特色图显示了套头衫科学家。通过胶结植物的照片。

没有新的文章